Literature DB >> 18505929

Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.

Jatin K Nagpal1, Sujit Nair, Dimple Chakravarty, Rajib Rajhans, Saikumar Pothana, Darrell W Brann, Rajeshwar Rao Tekmal, Ratna K Vadlamudi.   

Abstract

PELP1 (proline-rich, glutamic acid-rich, and leucine-rich protein-1) is a potential proto-oncogene that functions as a coregulator of estrogen receptor (ER), and its expression is deregulated during breast cancer progression. Emerging evidence suggests growth factor signaling crosstalk with ER as one possible mechanism by which breast tumors acquire resistance to therapy. In this study, we examined mechanisms by which growth factors modulate PELP1 functions, leading to activation of ER. Using in vivo labeling assays, we have found that growth factors promote phosphorylation of PELP1. Utilizing a panel of substrate-specific phosphorylated antibodies, we discovered that growth factor stimulation promotes phosphorylation of PELP1 that is recognized by a protein kinase A (PKA) substrate-specific antibody. Accordingly, growth factor-mediated PELP1 phosphorylation was effectively blocked by PKA-specific inhibitor H89. Utilizing purified PKA enzyme and in vitro kinase assays, we obtained evidence of direct PELP1 phosphorylation by PKA. Using deletion and mutational analysis, we identified PELP1 domains that are phosphorylated by PKA. Interestingly, site-directed mutagenesis of the putative PKA site in PELP1 compromised growth factor-induced activation and subnuclear localization of PELP1 and also affected PELP1-mediated transactivation function. Utilizing MCF-7 cells expressing a PELP1 mutant that cannot be phosphorylated by PKA, we provide mechanistic insights by which growth factor signaling regulates ER transactivation in a PELP1-dependent manner. Collectively, these findings suggest that growth factor signals promote phosphorylation of ER coactivator PELP1 via PKA pathway, and such modification may have functional implications in breast tumors with deregulated growth factor signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505929      PMCID: PMC2782677          DOI: 10.1158/1541-7786.MCR-07-2030

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

Review 1.  Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.

Authors:  Richard J Pietras
Journal:  Oncologist       Date:  2006 Jul-Aug

Review 2.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response.

Authors:  Michael G Rosenfeld; Victoria V Lunyak; Christopher K Glass
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

Review 3.  Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.

Authors:  Beverly Moy; Paul E Goss
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

4.  p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival.

Authors:  C Cosentino; M Di Domenico; A Porcellini; C Cuozzo; G De Gregorio; M R Santillo; S Agnese; R Di Stasio; A Feliciello; A Migliaccio; E V Avvedimento
Journal:  Oncogene       Date:  2006-10-02       Impact factor: 9.867

5.  Molecular biology. Little molecules with big goals.

Authors:  Bert W O'Malley
Journal:  Science       Date:  2006-09-22       Impact factor: 47.728

Review 6.  Coregulators: from whence came these "master genes".

Authors:  Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2007-02-06

7.  Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.

Authors:  Mariam H Al-Dhaheri; Brian G Rowan
Journal:  Mol Endocrinol       Date:  2006-10-26

8.  Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase.

Authors:  James G Greger; Natalie Fursov; Neil Cooch; Sean McLarney; Leonard P Freedman; Dean P Edwards; Boris J Cheskis
Journal:  Mol Cell Biol       Date:  2006-12-28       Impact factor: 4.272

9.  Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7.

Authors:  Emilie Gaillard; Nathalie Bruck; Yann Brelivet; Gaétan Bour; Sébastien Lalevée; Annie Bauer; Olivier Poch; Dino Moras; Cécile Rochette-Egly
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

View more
  20 in total

1.  Significance of ER-Src axis in hormonal therapy resistance.

Authors:  Sreeram Vallabhaneni; Binoj C Nair; Valerie Cortez; Rambabu Challa; Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res Treat       Date:  2010-12-24       Impact factor: 4.872

Review 2.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

3.  PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity.

Authors:  Sujit S Nair; Binoj C Nair; Valerie Cortez; Dimple Chakravarty; Eric Metzger; Roland Schüle; Darrell W Brann; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  EMBO Rep       Date:  2010-05-07       Impact factor: 8.807

4.  The histone variant MacroH2A1 regulates target gene expression in part by recruiting the transcriptional coregulator PELP1.

Authors:  Kristine M Hussey; Hongshan Chen; Christine Yang; Eugene Park; Nasun Hah; Hediye Erdjument-Bromage; Paul Tempst; Matthew J Gamble; W Lee Kraus
Journal:  Mol Cell Biol       Date:  2014-04-21       Impact factor: 4.272

Review 5.  PELP1: a key mediator of oestrogen signalling and actions in the brain.

Authors:  R Thakkar; G R Sareddy; Q Zhang; R Wang; R K Vadlamudi; D Brann
Journal:  J Neuroendocrinol       Date:  2018-02       Impact factor: 3.627

Review 6.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

Review 7.  PELP1--a novel estrogen receptor-interacting protein.

Authors:  Darrell W Brann; Quan-Guang Zhang; Rui-Min Wang; Virendra B Mahesh; Ratna K Vadlamudi
Journal:  Mol Cell Endocrinol       Date:  2008-05-13       Impact factor: 4.102

Review 8.  PELP1: Structure, biological function and clinical significance.

Authors:  Gangadhara Reddy Sareddy; Ratna K Vadlamudi
Journal:  Gene       Date:  2016-03-18       Impact factor: 3.688

9.  Extranuclear coactivator signaling confers insensitivity to tamoxifen.

Authors:  Rakesh Kumar; Hao Zhang; Caroline Holm; Ratna K Vadlamudi; Goran Landberg; Suresh K Rayala
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

Review 10.  PELP1: a review of PELP1 interactions, signaling, and biology.

Authors:  Brian J Girard; Andrea R Daniel; Carol A Lange; Julie H Ostrander
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.